Condition
Post COVID-19 Condition, Unspecified
Total Trials
6
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (2)
P 3 (2)
Trial Status
Completed4
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05852873Phase 3Active Not RecruitingPrimary
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
NCT05638620Phase 1Completed
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
NCT05823896Phase 2Completed
ImPROving Quality of LIFe in the Long COVID Patient
NCT04842448Phase 2Completed
Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome
NCT06267300Phase 3Not Yet Recruiting
Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial
NCT05911035Completed
Post-COVID-19 Mucormycosis in Critical Care
Showing all 6 trials